Advanced Search

  • Topic
  • Specialty
  • Content Type


Also Related

< Back To Patient Safety
0 dislikes

< Hide

Comments For

References: Colorectal Cancer Decision Support Tool


< Shrink

Add Your Voice

All comments are posted anonymously. Your comment will be attributed to: "Anonymous user."

post comment


Are you sure you want to delete this comment?

References: Colorectal Cancer Decision Support Tool

Related to: Clinical Guidelines, Communication, Diagnosis, Primary Care, Other Specialties

References 1–20
1. Lieberman DA, et al. Prevalence of colon polyps detected by colonoscopy screening in asymptomatic black and white patients. JAMA. 2008;300:1459–61.

2. Agrawal S,, et al. Colorectal cancer in African Americans. Am J Gastroenterol. 2005;100:515–23. 

3. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22;191–97. 

4. Okabayashi K,, et al. Body mass index category as a risk factor for colorectal adenomas: a systematic review and meta-analysis. Am J Gastroenterol. 2012;107:1175–85. 

5. Henderson TO,, et al. Secondary gastrointestinal malignancies in childhood cancer survivors: a cohort study. Ann Intern Med. 2012;156:757–66. 

6. Rodriquez, AM, Kuo YF, Goodwin JS. Risk of colorectal cancer among long-term cervical cancer survivors. Medical Oncology. 2014;31:943–52.  

7. Ashktorab H, et al. Racial disparity in gastrointestinal cancer risk. Gastroenterology. 2017;153: 910–23. 

8. Sheffield KM, et al. Potentially inappropriate screening colonoscopy in Medicare patients. JAMA. 2013;173:542–50. 

9. Torke AM, et al. Older adults and forgoing cancer screening. JAMA. 2013;173:526–31. 

10. Day LW, et al. Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis. Gastrointest Endosc. 2011;74:885–96.

11. Collins JF, et al. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med. 2005;142:81–5. 

12. Markowitz GS, et al. Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. J Am Soc Nephrol. 2005;16:3389–96. 

13. Khurana A, et al. The effects of oral sodium phosphate drug products on renal function in adults undergoing bowel endoscopy. Arch Intern Med. 2008:168(6):593–97..

14. Heher EC, et al. Adverse renal and metabolic effects associated with oral sodium phosphate bowel preparation. Clin J Am Soc Nephrol. 2008;3:1494–1503.  

15. Gurudu SR, et al. Increased adenoma detection rate with system-wide implementation of a split-dose preparation for colonoscopy. Gastrointest Endosc. 2012;76:603–8.

16. Burt RW. Colon Cancer Screening. Gastroenterology. 2000;119:837–53.

17. Graff RE, et al. Familial risk and heritability of colorectal cancer in the Nordic Twin Study of Cancer. Clin Gastroenterol Hepatol. 2017;1256–64. 

18. Strum WB. Colorectal adenomas. NEJM. 2017;374:1065–75.  

19. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med. 2003;138:560–70. 

20. Hampel H, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). NEJM. 2005;352:1851–60. 
 References 21–40
21. Lubbe SJ, et al. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol. 2009;27:3975–80.

22. Jasperson KW, et al. Hereditary and familial colon cancer. Gastroenterology. 2010;138:2044–58.

23. Bernstein CN, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91:854–62.

24. Beaugerie L, et al. Risk of colorectal high grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013;145:166–75.

25. Farraye FA, et al. AGA Technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:746–74.

26. Farraye FA, et al. AGA Medical Position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:738–45.

27. Nishihara R, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. NEJM. 2013;369:1095–105.

28. Doubeni CA., et al. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average risk adults. Ann Intern Med. 2013;158(5 Part 1):312–20.

29. Shaukat A, et al. Long-term mortality after screening for colorectal cancer. NEJM. 2013;369:1106–14.

30. Levin TR, et al. Colorectal-cancer screening-coming of age. NEJM. 2013:1164–66.
31. Lai EJ, et al. The Boston Bowel Preparation Scale: A valid and reliable instrument for colonoscopy-oriented research. Gastrointest Endosc. 2009;69(3 Pt 2):620–25 .

32. Whitlock EP, et al. Screening for colorectal cancer: A targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:638–58.  

33. Zauber AG, et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:659–69.

34. Brenner H, et al. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med. 2011;154:22–30.

35. USPSTF. Screening for colorectal cancer: recommendation statement. Ann Intern Med. 2008;149:680–82.

36. Zauber AG, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. NEJM. 2012;366:687–96.

37. Lieberman DA, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on colorectal cancer. Gastroenterology. 2012;143:844–57.

38. Lin JS, et al. Screening for colorectal cancer. updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2016;315:2576–94. 

39. Rex, DK, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointest Endosc. 2017;86:18–33.

40. Lieberman DA, et al. Screening for colorectal cancer and evolving issues for physicians and patients: a review. JAMA. 2016;316(20):2135–45.

References 41–60
41. Percac-Lima S, et al. Diagnostic evaluation of patients presenting to primary care with rectal bleeding. J Gen Intern Med. 2018;33(4):415–42.  

42. Siegel RL, et al. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2009;18:1695– 98.

43. Holowatyj AN, et al. Racial/ethnic disparities in survival among patients with young-onset colorectal cancer. J Clin Oncol. 2016;34:2148–56.

44. Meyer JE, et al. Increasing incidence of rectal cancer in patients aged younger than 40 years. Cancer. 2010;116:4354–59. 

45. Chen FW, et al. Advanced stage colorectal cancer in persons younger than 50 years not associated with longer duration of symptoms to time to diagnosis. Clin Gastroenterol Hepatol. 2017;15:728–37.  

46. Shields HM, et al. Disparities in evaluation of patients with rectal bleeding 40 years of age and older. Clin Gastroenterol Hepatol. 2014;12:669–75.

47. Karsenti D, et al. Adenoma detection rate according to age: colonoscopy screening should start at 45 years old, Presented at the 25th UEG Week Barcelona, October 30, 2017.  

48. Murphy CC, et al. Young-onset colorectal cancer: earlier diagnoses or increasing disease burden? Gastroenterology. 2017;152(8):1809–12.

49. Kaminski MF, et al. Quality indicators for colonoscopy and the risk of interval cancer. NEJM. 2010;362:1795–1803.

50. Robertson D, et al. Using the results of a baseline and a surveillance colonoscopy to predict recurrent adenomas with high-risk characteristics. Ann Intern Med. 2009;151:103–9.
51. Baxter NM, et al. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 2009;150:1–8.  

52. Ransohoff DF, et al. How much does colonoscopy reduce colon cancer mortality? Ann Intern Med. 2009;150:50–2.

53. Morikawa T, et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology. 2005;129:422–28.

54. Liles EG, et al. Change to FIT increased CRC screening rates: Evaluation of a US screening outreach program. Am J Manag Care. 2012;18: 588–95.

55. Murphy CC, et al. Underuse and overuse of colonoscopy for repeat screening and surveillance in the Veterans Health Administration. Clin Gastroenterol Hepatol. 2016;14(3):436–44.  

56. Qunitero E, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. NEJM. 2012;366:697–706.  

57. Inadomi JM, et al. Adherence to colorectal cancer screening. A randomized clinical trial of competing strategies. JAMA. 2012;172:575–82.

58. Robertson DJ, et al. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the U.S. Multi-society Task Force on Colorectal Cancer. Gastrointest Endosc. 2016;85:2–21

59. Akram A, et al. Replacing the guaiac fecal occult blood test with the fecal immunochemical test increases proportion of individuals screened in a large healthcare setting. Clin Gastroenterol Hepatol. 2017;15:1265–70.

60. van der Vlugt M, et al. Interval colorectal cancer incidence among subjects undergoing multiple rounds of fecal immunochemical testing.

References 61–70
61. Jensen CD, et al. Fecal immunochemical test program performance over 4 rounds of annual screening: a retrospective cohort study. Ann Intern Med. 2016;164:456–63.

62. Lee JK, et al. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014;160:171–81.

63. Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. NEJM. 2001;345:555–60.

64. Levi Z, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med. 2007;146:244–55.

65. Cash BD, et al. Clinical use of CT colonography for colorectal cancer screening in military training facilities and potential impact on HEDIS measures. J Am Coll Radiol. 2013;10:30–6.
66. Imperiale TF, et al. Multitarget stool DNA testing for colorectal-cancer screening. NEJM. 2014;370:1287–97.

. Lieberman DA, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer: Veterans Affairs Cooperative Study 380. NEJM. 2000;343:162–68.

68. Imperiale TF, et al. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. NEJM. 2000;343:169–74.

69. Kolb JM, et al. Detection, diagnosis and resection of sessile serrated adenomas and polyps. Gastroenterology. 2017;153:646–48.

70. Kahi CJ, et al. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2016;150:758–68.

References 71–82
71. Rex DK, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology. 1997;112:24–8.

72. Aslinia F, et al. Quality assessment of colonoscopic cecal intubation: an analysis of 6 years of continuous practice at a university hospital. Am J Gastroenterol. 2006;101:721–31.

73. Lee RH. Quality colonoscopy: a matter of time, technique or technology? World J Gastroenterol. 2013;19:1517–22.

74. Brenner H, et al. Role of colonoscopy and polyp characteristics in colorectal cancer after colonoscopic polyp detection. Ann Intern Med. 2012;157:225–32.

75. Rex DK, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012;107:1315–29.

76. Pohl H, et al. Incomplete polyp resection during colonoscopy: results of the complete adenoma resection (CARE) study. Gastroenterology. 2013;144:74–80.

77. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2012 Panel Members Colorectal Cancer Screening.

78. Kahi CJ, Rex DK. Why we should CARE about polypectomy technique. Gastroenterology. 2013;144:16–8.

79. Iannone A, et al. Chromoendoscopy for surveillance in ulcerative colitis and crohn’s disease: a systematic review of randomized trials. Clin Gastroenterol Hepatol. 2017;15:1684–97.

80. Giardiello FM, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2014;109:1159–79.

81. Umar A, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–68.

82. Bresalier RS. Colorectal Cancer. In: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. Ninth Edition. Eds. Mark Feldman, Lawrence S. Friedman, Lawrence J. Brandt. Philadelphia, Saunders Elsevier. 2010. p. 2208.

October 23, 2019
0 dislikes

< Back To Patient Safety